Generation of human neutralizing monoclonal antibodies against the 2009 pandemic H1N1 virus from peripheral blood memory B lymphocytes

Cellular and Molecular Immunology

Volumn 10, Issue 5, 2013, Pages 403-412

  Wang, Hao ^a   Ma, Chi ^a   Lu, Yanlai ^a   Ji, Xu ^a   Pang, Yongsheng ^a   Hua, Fang ^a   Cui, Lianxian ^a   Ba, Denian ^a   He, Wei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

2009 pandemic influenza H1N1 virus; Epstein Barr virus; Hemagglutinin; memory B cells; Neutralizing monoclonal antibody

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; PANFLU 1; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY AFFINITY; ARTICLE; BLOOD; CD19+ CD27+ MEMORY B CELL; CELL IMMORTALIZATION; CELL SCREENING; CLONE; EPSTEIN BARR VIRUS; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MEMORY CELL; NORMAL HUMAN; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CHINA; HEMAGGLUTINATION INHIBITION TESTS; HERPESVIRUS 4, HUMAN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEUTRALIZATION TESTS; PANDEMICS; VACCINATION;

EID: 84883366069     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2013.25     Document Type: Article

References (41)

1. de Whalley P, Pollard A. Pandemic influenza A (H1N1) 2009 vaccination in children: a UK perspective. J Paediatr Child Health 2013; 49: E183-E188.
2. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325: 197-201.
3. Brockwell-Staats C, Webster R, Webby R. Diversity of influenza viruses in swine and the emergence of a novel human pandemic influenza A (H1N1). Influenza Other Respir Viruses 2009; 3: 207-213.
4. Wrammert J, Koutsonanos D, Li G, Edupuganti S, Sui J, Morrissey M et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208: 181-193.
5. Liang X, Wang H, Wang J, Fang H, Wu J, Zhu F et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375: 56-66.
6. Kozbor D, Roder J, Chang T, Steplewski Z, Koprowski H. Human antitetanus toxoid monoclonal antibodies secreted by EBV-transformed human B cells fused with murine myelorna. Hybrodoma 1982; 1: 323-328.
7. Karpas A, Dremucheva A, Czepulkowski B. A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci USA 2001; 98: 1799-1804.
8. Steinitz M, Klein G, Koskimies S, Makel O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 1977; 269: 420-422.
9. Jin A, Ozawa T, Tajiri K, Obata T, Kondo S, Kinoshita K et al. A rapid and efficient single-cell manipulation method for screening antigenspecific antibody-secreting cells from human peripheral blood. Nat Med 2009; 15: 1088-1092.
10. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2: 52-62.
11. Jones P, Dear P, Foote J, Neuberger M, Winter G. Replacing the complementarity-determing regions in a human antibody with those from a mouse. Nature 1986; 321: 522-525.
12. McCafferty J, Griffiths A, Winter G, Chiswell D. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348: 552-554.
13. Sui J, Hwang W, Perez S, Wei G, Aird D, Chen L et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16: 265-273.
14. Green L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999; 231: 11-23.
15. Li G, Chiu C, Wrammert J, McCausland M, Andrews S, Zheng N et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 2012; 109: 9047-9052.
16. Henn A, Rebhahn J, Brown M, Murphy A, Coca M, Hyrien O et al. Modulation of single-cell IgG secretion frequency and rates in human memory B cells by CpG DNA, CD40L, IL-21, and cell division. J Immunol 2009; 183: 3177-3187.
17. Xi X, Guo Y, Chen H, Xu C, Zhang H, Hu H et al. Antigen specificity of gammadelta T cells depends primarily on the flanking sequences of CDR3delta. J Biol Chem 2009; 284: 27449-27455.
18. James E, Shaw R , Leung K. Growth of B95-8 cells and expression of Epstein-Barr Virus lytic phase in serum-free medium. J Virol 1987; 61: 4033-4037.
19. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo M et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004; 10: 871-875.
20. Li Z, Ma C, Liu Z, He W. Serologic cross-reactivity among humans and birds infected with highly pathogenic avian influenza A subtypeH5N1 viruses in China. Immunol Lett 2011; 135: 59-63.
21. Li Z, Liu Z, Ma C, Zhang L, Su Y, Gao G et al. Identification of amino acids in highly pathogenic avian influenza H5N1 virus hemagglutinin that determine avian influenza species specificity. Arch Virol 2011; 156: 1803-1812.
22. Lin X, Zhou J, Zhang Y, Wu J, Zhang F, Li Z et al. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro. Biochem Biophys Res Commun 2009; 390: 1305-1308.
23. Hoffmann E, Lipatov A, Webby R, Govorkova E, Webster R. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA 2005; 102: 12915-12920.
24. Yu X, Tsibane T, McGraw P, House F, Keefer C, Hicar M et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455: 532-536.
25. Wu J, Xu F, Lu L, Lu M, Miao L, Gao T et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing.NEngl JMed 2010; 363: 2416-2423.
26. Qiu Y , Yin W. Safety and immunogenicity of Sinovac's prototype pandemic influenza H5N1 vaccines: a review on clinical trials. Influenza Other Respi Viruses 2008; 2: 237-242.
27. Terajima M, Cruz J, Co MD, Lee JH, Kaur K, Wilson P et al. Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol 2011; 85: 13463-13467.
28. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D et al. A neutralizing antibody selected from plasma cells that binds to Group 1 and Group 2 influenza A Hemagglutinins. Science 2011; 333: 850-856.
29. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H et al. Crossreactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361: 1945-1952.
30. Corti D, Suguitan AJ, Pinna D, Silacci C, Fernandez-Rodriguez B, Vanzetta F et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120: 1663-1673.
31. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324: 246-251.
32. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333: 843-850.
33. Ekiert D, Wilson I. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol 2012; 2: 134-141.
34. Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, Tsibane T et al. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol 2010; 84: 127-130.
35. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM1 memory B cells. PLoS ONE 2008; 3: e3942.
36. An Z. Monoclonal antibodies-a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 2010; 1: 319-330.
37. Brocks B, Kraft S, Zahn S, Noll S, Pan C, SchauerM et al. Generation and optimization of human antagonistic antibodies against TIMP-1 as potential therapeutic agents in fibrotic diseases. Hum Antibodies 2006; 15: 115-124.
38. Zuidscherwoude M, van Spriel AB. The origin of IgE memory and plasma cells. Cell Mol Immunol 2012; 9: 373-374.
39. Zheng J, Liu Y, Lau Y, Tu W. Gammadelta-T cells: an unpolished sword in human anti-infection immunity. Cell Mol Immunol 2013; 10: 50-57.
40. Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004; 173: 1978-1986.
41. Wang X, Chan CC, Yang M, Deng J, Poon VK, Leung VH et al. A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection. Cell Mol Immunol 2011; 8: 462-468.